drugset / Trial / NCT06164821
Clinical Observation of Luspatercept in Treatment of Chinese Adult β-thalassaemia Patients With TD β-thalassemia
NaSingle-groupOpen-labelTreatment
Summary
To assesse the efficacy and safety of luspatercept versus placebo in China patients with transfusion-dependent β-thalassaemia.
Timeline
- Start
- 2024-01-01
- Primary completion
- 2024-01-01
- Completion
- 2024-11-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Luspatercept | Protein / enzyme biologic | 1.25 mg/kg | Subcutaneous |
Indications
No indication recorded.